{"id":"https://openalex.org/W4396597269","doi":"https://doi.org/10.1158/1538-7445.sabcs23-po1-18-05","title":"Abstract PO1-18-05: Combination treatment with CDK2 inhibitor (BLU-222) and either palbociclib or ribociclib is synergistic in pre-clinical models of CDK4/6 inhibitor-resistant breast cancer","display_name":"Abstract PO1-18-05: Combination treatment with CDK2 inhibitor (BLU-222) and either palbociclib or ribociclib is synergistic in pre-clinical models of CDK4/6 inhibitor-resistant breast cancer","publication_year":2024,"publication_date":"2024-05-02","ids":{"openalex":"https://openalex.org/W4396597269","doi":"https://doi.org/10.1158/1538-7445.sabcs23-po1-18-05"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.sabcs23-po1-18-05","doi":"https://doi.org/10.1158/1538-7445.sabcs23-po1-18-05","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs23-po1-18-05","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5016125750","display_name":"Linjie Luo","orcid":"https://orcid.org/0000-0002-2365-0327","observed_orcids":["https://orcid.org/0000-0002-2365-0327"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Linjie Luo","raw_affiliation_strings":["1Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017644527","display_name":"Juliana Navarro-Yepes","orcid":"https://orcid.org/0000-0003-0393-3773","observed_orcids":["https://orcid.org/0000-0003-0393-3773"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Juliana Navarro-Yepes","raw_affiliation_strings":["2The University of Texas MD Anderson Cancer Center, Houston, Texas, United States;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2The University of Texas MD Anderson Cancer Center, Houston, Texas, United States;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104293244","display_name":"Yan Wang","orcid":"https://orcid.org/0000-0001-9566-8975","observed_orcids":["https://orcid.org/0000-0001-9566-8975"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yan Wang","raw_affiliation_strings":["1Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000113218","display_name":"Tuyen N. Bui","orcid":"https://orcid.org/0000-0001-8509-3653","observed_orcids":["https://orcid.org/0000-0001-8509-3653"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tuyen Bui","raw_affiliation_strings":["2The University of Texas MD Anderson Cancer Center, Houston, Texas, United States;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2The University of Texas MD Anderson Cancer Center, Houston, Texas, United States;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026936750","display_name":"Nicole M. Kettner","orcid":"https://orcid.org/0000-0003-2043-4407","observed_orcids":["https://orcid.org/0000-0003-2043-4407"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nicole Kettner","raw_affiliation_strings":["2The University of Texas MD Anderson Cancer Center, Houston, Texas, United States;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2The University of Texas MD Anderson Cancer Center, Houston, Texas, United States;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110083321","display_name":"Debu Tripathy","orcid":"https://orcid.org/0000-0002-5711-2404","observed_orcids":["https://orcid.org/0000-0002-5711-2404"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Debu Tripathy","raw_affiliation_strings":["2The University of Texas MD Anderson Cancer Center, Houston, Texas, United States;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2The University of Texas MD Anderson Cancer Center, Houston, Texas, United States;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071536008","display_name":"Kelly Hunt","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kelly Hunt","raw_affiliation_strings":["2The University of Texas MD Anderson Cancer Center, Houston, Texas, United States;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2The University of Texas MD Anderson Cancer Center, Houston, Texas, United States;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Kerrie Faia","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kerrie Faia","raw_affiliation_strings":["3Blueprint Medicines Corporation, Cambridge, MA, Cambridge, Massachusetts, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Blueprint Medicines Corporation, Cambridge, MA, Cambridge, Massachusetts, United States","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5042960706","display_name":"Khandan Keyomarsi","orcid":"https://orcid.org/0000-0002-5440-0849","observed_orcids":["https://orcid.org/0000-0002-5440-0849"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Khandan Keyomarsi","raw_affiliation_strings":["1Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States;","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"84","issue":"9_Supplement","first_page":"PO1","last_page":"18"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cdk2-inhibitors","display_name":"CDK2 inhibitors","score":0.9750000238418579},{"id":"https://openalex.org/keywords/palbociclib","display_name":"palbociclib","score":0.9589999914169312},{"id":"https://openalex.org/keywords/ribociclib","display_name":"ribociclib","score":1.0},{"id":"https://openalex.org/keywords/cdk4-6-inhibitor-resistance","display_name":"CDK4/6 inhibitor resistance","score":0.9919999837875366},{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.6570000052452087},{"id":"https://openalex.org/keywords/hormone-receptor-positive-her2-negative-metastatic-breast-cancer","display_name":"hormone receptor-positive HER2-negative metastatic breast cancer","score":0.8619999885559082},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.621999979019165},{"id":"https://openalex.org/keywords/synergistic-effect","display_name":"synergistic effect","score":0.5870000123977661},{"id":"https://openalex.org/keywords/cyclin-e","display_name":"cyclin E","score":0.7689999938011169},{"id":"https://openalex.org/keywords/cdk2","display_name":"CDK2","score":0.6019999980926514},{"id":"https://openalex.org/keywords/patient-derived-xenografts","display_name":"patient-derived xenografts","score":0.8809999823570251},{"id":"https://openalex.org/keywords/endocrine-resistance","display_name":"endocrine therapy resistance","score":0.6499999761581421},{"id":"https://openalex.org/keywords/letrozole","display_name":"letrozole","score":0.7080000042915344},{"id":"https://openalex.org/keywords/fulvestrant","display_name":"fulvestrant","score":0.9959999918937683}],"concepts":[{"id":"https://openalex.org/C2779744173","wikidata":"https://www.wikidata.org/wiki/Q15269707","display_name":"Palbociclib","level":5,"score":0.9245753884315491},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6808968186378479},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.49762585759162903},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.48647066950798035},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.45751920342445374},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.44122034311294556},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.17009055614471436}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.sabcs23-po1-18-05","doi":"https://doi.org/10.1158/1538-7445.sabcs23-po1-18-05","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs23-po1-18-05","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4393095423","https://openalex.org/W4322774964","https://openalex.org/W7125398609","https://openalex.org/W4205928549","https://openalex.org/W4416947827","https://openalex.org/W3106785508","https://openalex.org/W4409821394","https://openalex.org/W4322771199","https://openalex.org/W3082042358","https://openalex.org/W4323570065"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Cyclin-dependent-kinase-4/6":[2],"inhibitors":[3,39,407],"(CDK4/6":[4],"inhibitors)":[5],"plus":[6,40,150,204,232,350,427],"endocrine":[7],"therapy":[8],"(ET)":[9],"is":[10,476],"the":[11,145,157,263,351,384,391,490],"standard":[12],"of":[13,87,116,127,142,148,166,200,228,246,348,369,386,401,481,489],"care":[14],"first-line":[15],"treatment":[16,315,344,368,430,466],"for":[17,424],"patients":[18,31,191,217,438],"with":[19,46,73,113,175,192,285,309,316,376,405,467],"hormone":[20],"receptor":[21],"(HR)-positive,":[22],"HER2-negative":[23],"metastatic":[24],"breast":[25,89,101,409,436,484],"cancer":[26,90,102,410,437,485],"(MBC).":[27],"However,":[28],"since":[29],"most":[30],"progress":[32],"following":[33,197,224,364],"long-term":[34],"treatment,":[35,206],"resistance":[36,194],"to":[37,92,202,230,262,273,280,342,393,417,431],"CDK4/6":[38,93,352,406,418,428,443,482],"ET":[41],"remains":[42],"a":[43,54,64,124,131,135,169,288,379,421],"clinical":[44,432],"problem":[45],"limited":[47],"therapeutic":[48],"options.":[49],"Here":[50],"we":[51],"show":[52,398],"that":[53],"potent":[55],"and":[56,81,97,122,144,188,207,214,241,249,256,299,321,358,372,413,471],"selective":[57],"CDK2":[58,250,468],"inhibitor,":[59],"BLU-222,":[60],"while":[61],"effective":[62],"as":[63,168,340,378],"single":[65,139,159,170,380],"agent,":[66,381],"exhibited":[67,331],"enhanced,":[68],"synergistic":[69,290,477],"activity":[70,141,334,400],"when":[71],"combined":[72],"palbociclib":[74,151,176,203,231,286,322,473],"or":[75,172,177,234,305,326,474],"ribociclib":[76,178,327,475],"in":[77,79,82,110,130,152,173,182,292,303,311,335,383,403,408,434,478],"both":[78],"vitro":[80,153,312],"vivo":[83],"(patient-derived":[84],"xenografts-PDX)":[85],"models":[86,185,211,375,415,480],"HR+/HER2-":[88],"resistant":[91,221,416],"inhibitors.":[94,444],"Methods:":[95],"MCF7":[96,240],"T47D":[98,242],"palbociclib-resistant":[99,239,373],"(PR)":[100],"cell":[103,300,411],"lines":[104,412],"were":[105,154,219,251,259,270,276],"generated":[106],"by":[107,162,296],"culturing":[108],"cells":[109,269,294,371,392],"media":[111],"supplemented":[112],"increasing":[114],"concentrations":[115],"palbociclib,":[117,274],"starting":[118],"at":[119],"1.2":[120],"\u00b5M":[121,129],"reaching":[123],"final":[125],"concentration":[126],"4.8":[128],"stepwise":[132],"manner":[133],"over":[134],"6-month":[136],"period.":[137],"The":[138,164,346],"agent":[140,160,171],"BLU-222":[143,149,167,284,317,349,377,402,426],"combination":[146,174,314,347,404],"effect":[147,291],"evaluated":[155],"using":[156],"highest":[158],"model":[161],"SynergyFinder.":[163],"efficacy":[165],"was":[179],"also":[180],"assessed":[181],"two":[183,209],"PDX":[184,210,338,374,414],"(PR":[186,212],"1":[187],"2)":[189],"from":[190,216],"acquired":[193],"(i.e.":[195,222],"progressed":[196,223,441],">6":[198],"months":[199,227],"treatment)":[201,229],"letrozole":[205],"another":[208],"3":[213,226],"4)":[215],"who":[218,439],"intrinsically":[220],"<":[225],"fulvestrant":[233],"letrozole,":[235],"respectively.":[236],"Results:":[237],"In":[238],"cells,":[243],"protein":[244],"levels":[245,258],"cyclin":[247],"E":[248],"significantly":[252,277],"upregulated,":[253],"but":[254],"Rb":[255],"p21":[257],"downregulated":[260],"compared":[261,341],"parental":[264],"cells.":[265],"While":[266],"these":[267,310],"PR":[268,293,370],"completely":[271],"refractory":[272],"they":[275],"more":[278],"sensitive":[279],"BLU-222.":[281],"Moreover,":[282],"combining":[283],"demonstrated":[287],"strong":[289,422],"accompanied":[295],"enhanced":[297],"apoptosis":[298],"cycle":[301],"accumulation":[302],"G1":[304],"G2/M":[306],"phases.":[307],"Consistent":[308],"findings,":[313],"(60":[318],"mg/kg;":[319,324,329],"b.i.d.)":[320],"(50":[323,328],"q.d.)":[325,330],"significant":[332],"antitumor":[333],"all":[336],"four":[337],"models,":[339],"either":[343,472],"alone.":[345],"inhibitor":[353,429,469],"induced":[354],"durable":[355],"tumor":[356],"regression":[357],"prolonged":[359],"survival,":[360],"which":[361,388],"continued":[362],"unabated":[363],"drug":[365],"removal.":[366],"Mechanistically,":[367],"resulted":[382],"induction":[385],"p21,":[387],"can":[389],"sensitize":[390],"palbociclib.":[394],"Conclusions:":[395],"These":[396],"results":[397],"robust":[399],"inhibitors,":[419],"providing":[420],"rationale":[423],"advancing":[425],"development":[433],"HR-positive/HER2-negative":[435],"have":[440],"on":[442],"Citation":[445],"Format:":[446],"Linjie":[447],"Luo,":[448],"Juliana":[449],"Navarro-Yepes,":[450],"Yan":[451],"Wang,":[452],"Tuyen":[453],"Bui,":[454],"Nicole":[455],"Kettner,":[456],"Debu":[457],"Tripathy,":[458],"Kelly":[459],"Hunt,":[460],"Kerrie":[461],"Faia,":[462],"Khandan":[463],"Keyomarsi.":[464],"Combination":[465],"(BLU-222)":[470],"pre-clinical":[479],"inhibitor-resistant":[483],"[abstract].":[486],"In:":[487],"Proceedings":[488],"2023":[491,497],"San":[492,500],"Antonio":[493],"Breast":[494],"Cancer":[495,506],"Symposium;":[496],"Dec":[498],"5-9;":[499],"Antonio,":[501],"TX.":[502],"Philadelphia":[503],"(PA):":[504],"AACR;":[505],"Res":[507],"2024;84(9":[508],"Suppl):Abstract":[509],"nr":[510],"PO1-18-05.":[511]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1}],"updated_date":"2026-09-27T08:07:27.782135","created_date":"2024-05-03T00:00:00"}